Cellectar Biosciences Inc (CLRB) - Financial and Strategic SWOT Analysis Review
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Cellectar Biosciences Inc (CLRB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Cellectar Biosciences Inc (Cellectar), is a biopharmaceutical company that discovers, develops and commercializes drugs for treatment of cancer. The companys proprietary technology, phospholipid drug conjugates (PDC) delivery platform that develops PDCs for the treatment and diagnosis of cancer. Its lead product, CLR 131, is a small-molecule PDC, in phase II clinical trials for the treatment of relapse or refractory multiple myeloma and B-cell lymphomas. The company is also evaluating CLR 131 in Phase I clinical trials for treatment of Pediatric patients with solid tumors, lymphomas; malignant brain tumors, head and neck cancer. Cellectars other products in pipeline include CLR 1800, CLR 1900, CLR 2000, CLR 2100, CLR 2200 and CLR 12120 for solid tumors. The companys seeks in collaboration with Orano Med, Onconova Therapeutics; Avicenna Oncology and University of Wisconsin. Cellectar is headquartered in Florham Park, New Jersey, the US.
Cellectar Biosciences Inc Key Recent Developments
Jul 01,2020: Cellectar appoints Dr. John Friend as Chief Medical Officer
Jun 01,2020: Cellectar granted SME status by the European Medicines Agency
May 07,2020: Cellectar reports first quarter 2020 financial results and provides a corporate update
Mar 09,2020: Cellectar reports financial results for year ended December 31, 2019 and provides a corporate update
Jan 19,2020: Cellectar Biosciences to present at Biotech Showcase 2020
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
The profile contains critical company information including:
- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Cellectar Biosciences Inc (Cellectar), is a biopharmaceutical company that discovers, develops and commercializes drugs for treatment of cancer. The companys proprietary technology, phospholipid drug conjugates (PDC) delivery platform that develops PDCs for the treatment and diagnosis of cancer. Its lead product, CLR 131, is a small-molecule PDC, in phase II clinical trials for the treatment of relapse or refractory multiple myeloma and B-cell lymphomas. The company is also evaluating CLR 131 in Phase I clinical trials for treatment of Pediatric patients with solid tumors, lymphomas; malignant brain tumors, head and neck cancer. Cellectars other products in pipeline include CLR 1800, CLR 1900, CLR 2000, CLR 2100, CLR 2200 and CLR 12120 for solid tumors. The companys seeks in collaboration with Orano Med, Onconova Therapeutics; Avicenna Oncology and University of Wisconsin. Cellectar is headquartered in Florham Park, New Jersey, the US.
Cellectar Biosciences Inc Key Recent Developments
Jul 01,2020: Cellectar appoints Dr. John Friend as Chief Medical Officer
Jun 01,2020: Cellectar granted SME status by the European Medicines Agency
May 07,2020: Cellectar reports first quarter 2020 financial results and provides a corporate update
Mar 09,2020: Cellectar reports financial results for year ended December 31, 2019 and provides a corporate update
Jan 19,2020: Cellectar Biosciences to present at Biotech Showcase 2020
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
TABLE OF CONTENTS
Section 1 - About the Company
Cellectar Biosciences Inc - Key Facts
Cellectar Biosciences Inc - Key Employees
Cellectar Biosciences Inc - Key Employee Biographies
Cellectar Biosciences Inc - Major Products and Services
Cellectar Biosciences Inc - History
Cellectar Biosciences Inc - Company Statement
Cellectar Biosciences Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 Company Analysis
Company Overview
Cellectar Biosciences Inc - Business Description
Cellectar Biosciences Inc - SWOT Analysis
SWOT Analysis - Overview
Cellectar Biosciences Inc - Strengths
Cellectar Biosciences Inc - Weaknesses
Cellectar Biosciences Inc - Opportunities
Cellectar Biosciences Inc - Threats
Cellectar Biosciences Inc - Key Competitors
Section 3 Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 Companys Lifesciences Financial Deals and Alliances
Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Cellectar Biosciences Inc, Recent Deals Summary
Section 5 Companys Recent Developments
Jul 01, 2020: Cellectar appoints Dr. John Friend as Chief Medical Officer
Jun 01, 2020: Cellectar granted SME status by the European Medicines Agency
May 07, 2020: Cellectar reports first quarter 2020 financial results and provides a corporate update
Mar 09, 2020: Cellectar reports financial results for year ended December 31, 2019 and provides a corporate update
Jan 19, 2020: Cellectar Biosciences to present at Biotech Showcase 2020
Jan 07, 2020: Cellectar appoints Dr. Igor Grachev as Chief Medical Officer
Nov 12, 2019: Cellectar reports third quarter 2019 financial results and provides a corporate update
Aug 15, 2019: Cellectar appoints Dov Elefant as chief financial officer
Aug 14, 2019: Cellectar reports second quarter 2019 financial results and provides a corporate update
May 06, 2019: Cellectar Reports First Quarter 2019 Financial Results and Provides a Corporate Update
Section 6 Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List Of Tables
Cellectar Biosciences Inc, Key Facts
Cellectar Biosciences Inc, Key Employees
Cellectar Biosciences Inc, Key Employee Biographies
Cellectar Biosciences Inc, Major Products and Services
Cellectar Biosciences Inc, History
Cellectar Biosciences Inc, Subsidiaries
Cellectar Biosciences Inc, Key Competitors
Cellectar Biosciences Inc, Ratios based on current share price
Cellectar Biosciences Inc, Annual Ratios
Cellectar Biosciences Inc, Annual Ratios (Cont...1)
Cellectar Biosciences Inc, Interim Ratios
Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Cellectar Biosciences Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List Of Figures
Cellectar Biosciences Inc, Performance Chart (2015 - 2019)
Cellectar Biosciences Inc, Ratio Charts
Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020
RELATED REPORTS
Interpace Biosciences Inc (IDXG) - Product Pipeline Analysis, 2020 Update
Interpace Biosciences Inc (Interpace Biosciences) formerly Interpace Diagnostics Group Inc, is a developer of molecular diagnostics tests. The company offers PancraGen, a DNA based molecular test that aids in pancreatic
View ReportAkers Biosciences Inc (AKER) - Product Pipeline Analysis, 2020 Update
Akers Biosciences Inc (ABI) is a medical device company that develops, manufactures and supplies point-of-care screening and testing products. The company provides clinical diagnostics, safety diagnostics, and wellness products. ABI
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
